News Headlines Article

FDA approves another in a new class of cholesterol-fighting drugs
Washington Post

The Food and Drug Administration on Thursday approved the second in a new class of cholesterol-lowering drugs aimed at helping certain people lower their risk of strokes and heart attacks, the leading annual cause of death in the United States.

The agency approved Repatha, an injectable drug manufactured by California-based Amgen, for a limited set of patients unable to get their LDL, or “bad,” cholesterol levels under control with typical treatments. The indications include use in people with familial hypercholesterolemia, a genetic disorder that can severely elevate LDL levels, as well as for patients who have had heart attacks and other serious cardiovascular problems and still cannot reach target LDL levels through the use of traditional statin drugs.